论文部分内容阅读
Pike等(1983)的流行病学研究报告妇女用含高效孕激素类口服避孕药可增加乳腺癌的发病率,不仅对研究结论而且对评价孕激素强度的临床试验方法的可靠性引起了极大争议。乞今尚无用同一种标准内分泌测定方法,对几种孕激素进行评价的报道。因此,作者采用随机实验设计,同时做几种内分泌测定,比较了6种孕激素制剂:即炔诺酮(NET),18甲基炔诺酮(LNG),地索高诺酮(desogestrel),甲孕酮(MPA),孕酮(P)和醋高诺酮肟(norgestimate)的强度和活性。
Epidemiological studies by Pike et al. (1983) reported that women using estrogen-containing oral contraceptives increased the incidence of breast cancer and caused a great deal of research not only on the conclusions of the study but also on the reliability of the clinical trial to assess the intensity of progestin dispute. Begging now useless with the same standard endocrine assay, the evaluation of several progesterone reported. Therefore, the authors used a randomized trial design and performed several endocrine assays simultaneously comparing six progestin agents: NET, 18 norethisterone (LNG), desogestrel, (MPA), progesterone (P) and norgestimate.